CTRI/2023/09/057974CompletedPhase 2
A prospective, open-label, 4 arm study to evaluate the safety and efficacy of Skin care product for its non-comedogenic effect in healthy male or female volunteers - NI
Kreative Beauty Private Limited0 sites60 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1.Healthy Indian male/female healthy volunteers aged between 18-55 years.
- •2.Willing to give Informed Consent Form.
- •3.Mild to moderate Black heads on the face
- •4.Willing to complete the study assessments/questionnaires.
- •5.Willing to avoid usage of his/her own moisturizers and face
- •6.serum for at least one week before Commencement and during this study.
Exclusion Criteria
- •1.Pregnancy or breast feeding.
- •2.Patients with pre-existing severe systemic disease necessitating long-term medication.
- •3.Patients with mild to severe Anaphylaxis reactions.
- •4.Evidence of significant uncontrolled co-morbid disease.
- •5.Historyofcancer,includingsolidtumors,hematologic malignancies and carcinoma in situ
- •6.Any neurological (congenital or acquired), vascular or systemic disorder which could affect any of the efficacy assessments.
- •7.Participation in the current or previous clinical trial with any approved or investigational products during the past 1 month.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 19.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-PLBoehringer Ingelheim RCV GmbH & Co KG282
Active, not recruiting
Phase 1
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 17.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-ROBoehringer Ingelheim RCV GmbH & Co KG70
Completed
Phase 4
A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants Receiving Emetogenic ChemotherapySymptomen en algemene pathologieChemotherapy-Induced Nausea and VomitingNL-OMON48224Merck Sharp & Dohme (MSD)6
Active, not recruiting
Phase 1
Three-day Fosaprepitant Regimen CINV Safety Study in Pediatric ParticipantsPrevention of Chemotherapy-Induced Nausea and Vomiting (CINV)MedDRA version: 21.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-004844-43-GRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
Active, not recruiting
Phase 1
Three-day Fosaprepitant Regimen CINV Safety Study in Pediatric ParticipantsPrevention of Chemotherapy-Induced Nausea and Vomiting (CINV)MedDRA version: 20.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-004844-43-NLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100